UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

F	O	R	M	R.	·K
L	V	T.	TAT.	O-	. Т.

CURRENT REPORT
Under Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
April 25, 2024

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware(State or Other Jurisdiction of Incorporation)

Emerging growth company \square

001-15317 (Commission File Number)

98-01528 (I.R.S. Emplo Identification

9001 Spectrum Center Blvd. San Diego, California 92123 (Address of Principal Executive Offices)

(858) 836-5000 (Registrant's telephone number, including area code)

	eck the appropriate box below if the Fo istrant under any of the following prov	orm 8-K filing is intended to simultaneou	ısly satisfy the filing obl		
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 24				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 24				
Sec	curities registered pursuant to Section	12(b) of the Act:			
	Title of each class	Trading Symbol(s)	Name of each ex on which regis		
	Common Stock, \$0.004 par value	RMD	NYSE		
		strant is an emerging growth company a Rule 12b-2 of the Securities Exchange A			

If an emerging growth company, indicate by check mark if the registrant has elected not to use the exterperiod for complying with any new or revised financial accounting standards provided pursuant to Section Exchange Act

Item 2.02. Results of Operations and Financial Condition.

On April 25, 2024, we issued the press release furnished as Exhibit 99.1. The press release describes the operations for the quarter ended March 31, 2024.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit s deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Excincorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange A shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On April 25, 2024, we announced that our board of directors declared a quarterly cash dividend of US \$0. The dividend will have a record date of May 9, 2024, payable on June 13, 2024. The dividend will be paid currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of CH Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australia based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE she ex-dividend date will be May 8, 2024, for common stockholders and for CDI holders. ResMed has receive from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between stock and CDI registers from May 8, 2024, through May 9, 2024, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits:	Description of Document
99.1	Press Release dated April 25, 2024, regarding results of operations
104	Cover Page Interactive Data File (embedded within the Inline XBRL, document)

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in according Exchange Act of 1934.

Date: April 25, 2024

RESMED INC.

(registrant)

By: /s/ Brett Sandercock

Name: Brett Sandercock Its: Chief Financial Officer

-3-